. Author manuscript; available in PMC: 2014 Oct 16.

Published in final edited form as: Cancer. 2008 Oct 15;113(8):2097–2101. doi: 10.1002/cncr.23819

TABLE 2.

Response to Induction Therapy

Response	No. of Patients (%)			P
	Aged ≥60 Years		Aged <60 Years
	Hyper-CVAD, n=122	Other Regimens, n=34	Hyper-CVAD, n=409
CR	102 (84)	20 (59)	378 (92)	<.001
PR	1 (1)	1 (3)	0
CRp	0 (0)	0 (0)	2 (1)
CR at start	1 (1)	0 (0)	12 (3)
Induction mortality	12 (10)	4 (12)	9 (2)	<.001
Resistant disease	6 (5)	9 (27)	8 (2)	<.001

Hyper-CVAD indicates hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone (8 courses alternating with high doses of methotrexate and cytarabine followed by maintenance with 6-mercaptopurine, vincristine, methotrexate, and prednisone); CR, complete response; PR, partial response; CRp, pathologic complete response.